Improvement in survival associated with embolisation of spontaneous portosystemic shunt in patients with recurrent hepatic encephalopathy

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 12, 2014, Pages 1418-1426

  An, J ^a   Kim, K W ^a   Han, S ^a   Lee, J ^b   Lim, Y S ^a  

^a University of Ulsan   (South Korea)

^b Soongsil University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; LIVER WEIGHT; MALE; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SPONTANEOUS PORTOSYSTEMIC SHUNT; SURVIVAL RATE; SURVIVAL TIME;

AGED; COHORT STUDIES; EMBOLIZATION, THERAPEUTIC; END STAGE LIVER DISEASE; FEMALE; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PORTASYSTEMIC SHUNT, SURGICAL; RETROSPECTIVE STUDIES;

EID: 84901487101     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12771     Document Type: Article

References (36)

1. Ferenci P, Lockwood A, Mullen K, et al,. Hepatic encephalopathy- definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-21.
2. Poordad FF,. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther 2007; 25 (Suppl. 1): 3-9.
3. Khungar V, Poordad F,. Hepatic encephalopathy. Clin Liver Dis 2012; 16: 301-20.
4. Bustamante J, Rimola A, Ventura PJ, et al,. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999; 30: 890-5.
5. Crespin J, Nemcek A, Rehkemper G, Blei AT,. Intrahepatic portal-hepatic venous anastomosis: a portal-systemic shunt with neurological repercussions. Am J Gastroenterol 2000; 95: 1568-71.
6. Bajaj JS,. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther 2010; 31: 537-47.
7. Riggio O, Efrati C, Catalano C, et al,. High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study. Hepatology 2005; 42: 1158-65.
8. Ohnishi K, Sato S, Saito M, et al,. Clinical and portal hemodynamic features in cirrhotic patients having a large spontaneous splenorenal and/or gastrorenal shunt. Am J Gastroenterol 1986; 81: 450-5.
9. Cordoba J,. New assessment of hepatic encephalopathy. J Hepatol 2011; 54: 1030-40.
10. Laleman W, Simon-Talero M, Maleux G, et al,. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology 2013; 57: 2448-57.
11. Uflacker R, Silva Ade O, d'Albuquerque LA, Piske RL, Mourao GS,. Chronic portosystemic encephalopathy: embolization of portosystemic shunts. Radiology 1987; 165: 721-5.
12. Boixadera H, Tomasello A, Quiroga S, et al,. Successful embolization of a spontaneous mesocaval shunt using the Amplatzer Vascular Plug II. Cardiovasc Intervent Radiol 2010; 33: 1044-8.
13. Mukund A, Rajesh S, Arora A, et al,. Efficacy of balloon-occluded retrograde transvenous obliteration of Large spontaneous lienorenal shunt in patients with severe recurrent hepatic encephalopathy with foam sclerotherapy: initial experience. J Vasc Interv Radiol 2012; 23: 1200-6.
14. Gwon DI, Ko GY, Yoon HK, et al,. Gastric varices and hepatic encephalopathy: treatment with vascular plug and gelatin sponge-assisted retrograde transvenous obliteration-a primary report. Radiology 2013; 268: 281-7.
15. Kumamoto M, Toyonaga A, Inoue H, et al,. Long-term results of balloon-occluded retrograde transvenous obliteration for gastric fundal varices: hepatic deterioration links to portosystemic shunt syndrome. J Gastroenterol Hepatol 2010; 25: 1129-35.
16. Blei AT, Cordoba J,; Practice Parameters Committee of the American College of G. Hepatic encephalopathy. Am J Gastroenterol 2001; 96: 1968-76.
17. Bajaj JS, Cordoba J, Mullen KD, et al,. Review article: the design of clinical trials in hepatic encephalopathy-an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther 2011; 33: 739-47.
18. Mullen KD,. Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy. Aliment Pharmacol Ther 2007; 25 (Suppl 1): 11-6.
19. Torlot FJ, McPhail MJ, Taylor-Robinson SD,. Meta-analysis: the diagnostic accuracy of critical flicker frequency in minimal hepatic encephalopathy. Aliment Pharmacol Ther 2013; 37: 527-36.
20. Salam M, Matherly S, Farooq IS, et al,. Modified-orientation log to assess hepatic encephalopathy. Aliment Pharmacol Ther 2012; 35: 913-20.
21. Sanyal A, Younossi ZM, Bass NM, et al,. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy-a double-blind placebo-controlled study. Aliment Pharmacol Ther 2011; 34: 853-61.
22. Bajaj JS, Sanyal AJ, Bell D, Gilles H, Heuman DM,. Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients. Aliment Pharmacol Ther 2010; 31: 1012-7.
23. Kim KW, Lee J, Lee H, et al,. Right lobe estimated blood-free weight for living donor liver transplantation: accuracy of automated blood-free CT volumetry-preliminary results. Radiology 2010; 256: 433-40.
24. Sakurabayashi S, Sezai S, Yamamoto Y, Hirano M, Oka H,. Embolization of portal-systemic shunts in cirrhotic patients with chronic recurrent hepatic encephalopathy. Cardiovasc Intervent Radiol 1997; 20: 120-4.
25. Watanabe K, Kimura K, Matsutani S, Ohto M, Okuda K,. Portal hemodynamics in patients with gastric varices. A study in 230 patients with esophageal and/or gastric varices using portal vein catheterization. Gastroenterology 1988; 95: 434-40.
26. Jiao LR, Seifalian AM, Mathie RT, Habib N, Davidson BR,. Portal flow augmentation for liver cirrhosis. Br J Surg 2000; 87: 984-91.
27. Zidi SH, Zanditenas D, Gelu-Simeon M, et al,. Treatment of chronic portosystemic encephalopathy in cirrhotic patients by embolization of portosystemic shunts. Liver Int 2007; 27: 1389-93.
28. Leithead JA, Hayes PC, Ferguson JW,. Review article: advances in the management of patients with cirrhosis and portal hypertension-related renal dysfunction. Aliment Pharmacol Ther 2014; 39: 699-711.
29. Cardoso JE, Giroux L, Kassissia I, et al,. Liver function improvement following increased portal blood flow in cirrhotic rats. Gastroenterology 1994; 107: 460-7.
30. Marcellin P, Heathcote EJ, Buti M, et al,. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.
31. Fried MW, Shiffman ML, Reddy KR, et al,. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
32. Rutter K, Hofer H, Beinhardt S, et al,. Durability of SVR in chronic hepatitis C patients treated with peginterferon-alpha2a/ribavirin in combination with a direct-acting anti-viral. Aliment Pharmacol Ther 2013; 38: 118-23.
33. Marcellin P, Gane E, Buti M, et al,. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-75.
34. Chang TT, Liaw YF, Wu SS, et al,. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-93.
35. D'Ambrosio R, Aghemo A, Rumi MG, et al,. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 2012; 56: 532-43.
36. Herrero JI, Bilbao JI, Diaz ML, et al,. Hepatic encephalopathy after liver transplantation in a patient with a normally functioning graft: treatment with embolization of portosystemic collaterals. Liver Transpl 2009; 15: 111-4.